Rory Riggs Net Worth (2024) – wallmine.com (2024)

Last updated: 2 July 2024 at 8:00pm EST

The estimated Net Worth of Rory B Riggs is at least $235 Million dollars as of 23 June 2024. Mr. Riggs owns over 21,567 units of FibroGen Inc stock worth over $48,425 and over the last 11 years he sold FGEN stock worth over $234,240,671. In addition, he makes $425,565 as Independent Director at FibroGen Inc.

Mr. Riggs FGEN stock SEC Form 4 insiders trading

Rory has made over 31 trades of the FibroGen Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 21,567 units of FGEN stock worth $337,092 on 23 June 2024.

The largest trade he's ever made was selling 1,750,000 units of FibroGen Inc stock on 22 May 2023 worth over $57,435,000. On average, Rory trades about 60,035 units every 37 days since 2014. As of 23 June 2024 he still owns at least 121,062 units of FibroGen Inc stock.

You can see the complete history of Mr. Riggs stock trades at the bottom of the page.

RoryRiggs biography

Rory B. Riggs serves as Independent Director of the Company. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax, LLC and Locus Analytics, LLC, sister development-stage ventures focused on creating a new information technology platform for business and finance. Mr. Riggs is co-founder and Chairman of Royalty Pharma, the largest acquirer of drug royalties, and Cibus Global Ltd., the leading company in gene editing in agriculture. In addition, he sits on the following other boards of directors: Intra-Cellular Therapies, Inc., Nuredis, Inc., GeneNews, Ltd. and eReceivables, LLC (Chair). Since June 2006, Mr. Riggs has also served as managing member of New Ventures, a series of venture funds focused on biotechnology and healthcare. Mr. Riggs served as the President of Biomatrix, Inc., a biomedical company, from 1996 until 2000. From 1991 to 1995, he was Chief Executive Officer of RF&P Corporation, an investment company owned by the Virginia Retirement System. He was also Managing Director of PaineWebber and Company, in the mergers and acquisitions department. Mr. Riggs holds a Bachelor of Arts degree from Middlebury College, Vermont and a Master of Business Administration degree from Columbia University.

What is the salary of Rory Riggs?

As the Independent Director of FibroGen Inc, the total compensation of Rory Riggs at FibroGen Inc is $425,565. There are 13 executives at FibroGen Inc getting paid more, with Kin-HungYu having the highest compensation of $5,856,450.

How old is Rory Riggs?

Rory Riggs is 67, he's been the Independent Director of FibroGen Inc since 1993. There are 3 older and 18 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is ThomasKearns, 83, who is the Lead Independent Director.

What's Rory Riggs's mailing address?

Rory's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.

Insiders trading at FibroGen Inc

Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423. The most active insiders traders include Rory B Riggs, Thomas B Neff und Jeffrey William Henderson.On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.

What does FibroGen Inc do?

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.

What does FibroGen Inc's logo look like?

FibroGen Inc executives and stock owners

FibroGen Inc executives and other stock owners filed with the SEC include:

• Kin-HungYu,
  Chief Medical Officer
• JamesSchoeneck,
  Chairman of the Board
• EliasKouchakji,
  Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
• ChristineChung,
  Senior Vice President, China Operations
• PatCotroneo,
  Chief Financial Officer
• Enrique A. Conterno,
  CEO & Director
• Dr. Elias Kouchakji,
  Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
• Pat Cotroneo,
  Exec. Advisor to CEO
• SuzanneBlaug,
  Independent Director
• Thane Wettig,
  Chief Commercial Officer
• Dr. Mark Eisner M.D., M.P.H.,
  Chief Medical Officer
• ThomasKearns,
  Lead Independent Director
• JeffreyEdwards,
  Independent Director
• RoryRiggs,
  Independent Director
• GeraldLema,
  Independent Director
• JeffreyHenderson,
  Independent Director
• MaykinHo,
  Independent Director
• KaleviKurkijarvi,
  Independent Director
• ToshinariTamura,
  Independent Director
• James A. Schoeneck,
  Chairman
• BenjaminCravatt,
  Director
• AoifeBrennan,
  Director
• ThaneWettig,
  Chief Commercial Officer
• PercyCarter,
  Chief Scientific Officer
• EnriqueConterno,
  Chief Executive Officer, Director
• Dr. John J. Hunter Ph.D.,
  Chief Scientific Officer
• Dr. Michael J. Martinelli,
  Sr. VP of Technical Devel.
• Juan Graham,
  Chief Financial Officer
• Dr. Barry A. Berkowitz Ph.D.,
  Founder
• Jorma Routti,
  Director
• K Peony Yu,
  Chief Medical Officer
• Thomas B Neff,
  Chief Executive Officer
• Mark Eisner,
  EVP, Chief Medical Officer
• Julian N Stern,
  Director
• Frank H Md Valone,
  Chief Medical Officer
• Miguel Madero,
  Director
• Pharma Inc. Astellas,
  
• Juan Graham,
  CHIEF FINANCIAL OFFICER
• Deyaa Adib,
  Chief Medical Officer